Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
23.8
%Wording
Conditional
How definitive the wording is.Results for this period
Full year2024年4月1日〜2025年3月31日ConsolidatedJapanese GAAPNet Sales33,231¥ millionYear on year +2.6%Progress 89.8%
Operating profit1,562¥ millionYear on year -23.8%Progress 78.1%
Ordinary income1,333¥ millionYear on year -35.3%Progress 83.3%
Net income attributable to owners of the parent1,092¥ millionYear on year -44.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share36.10円
Operating MarginCurrent fiscal year 4.7 % / Previous period 6.3 %
Financial position at period-end
Total assets51,760¥ million
of which net assets 18,385 ¥ millionEquity ratio 34.9%vs. prior year-end -0.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+2,978
Investment-4,574
Financials-1,127
Net change-2,723
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥7,078 million
Segment revenueContact Lenses and Lens Care Products ¥33,104,817 thousand (YoY +2.6%), Other ¥126,816 thousand (YoY +9.4%)
Segment profitContact Lenses and Lens Care Products ¥3,198,932 thousand (YoY -2.3%), Other ¥-8,961 thousand
Regional sales¥28,920,475 thousand, ¥1,108,754 thousand, ¥440,371 thousand, ¥2,739,229 thousand, ¥22,802 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥37,000 million (YoY +11.3%)
Operating profit¥2,000 million (YoY +28.0%)
Ordinary income¥1,600 million (YoY +20.0%)
Profit attributable to owners of the parent¥1,100 million (YoY +0.7%)
Annual Dividend Forecast¥15 → ¥15（0.0%）
Payout ratioCurrent fiscal year 41.6 % / Next-year forecast 41.3 %
Factors Behind Changes in Business Performance
設備増設に比例した生産の実現に時間を要したことと、機械トラブルによりPureシリーズを中心に生産量が伸び悩み、予定通りの製品供給に至らなかった。利益面では、生産効率の低下による製造原価の高騰、円安による輸入価格の上昇、本社移転費用、人件費の増加、治験に伴う研究開発費の高水準が影響した。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Material subsequent events連結子会社CLPL社が2025年4月1日付でScotlens Holdings Limitedの全株式を取得した。取得価額は￡2,404,187.50。
Impairment loss¥8,788 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥4,066 thousand / Extraordinary loss Impairment Losses ¥8,788 thousand, Loss on Disposal of Fixed Assets ¥1,893 thousand
Depreciation and amortization¥3,319,505 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End30,265,922
Treasury Shares at Period-End136
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2025年3月31日 |
| Net Sales | ¥33,231 million (YoY +2.6%) |
| Operating profit | ¥1,562 million (YoY -23.8%) |
| Ordinary income | ¥1,333 million (YoY -35.3%) |
| Profit attributable to owners of the parent | ¥1,092 million (YoY -44.4%) |
| Net income per share | 36.10円 |
| Operating Margin | Current fiscal year 4.7 % / Previous period 6.3 % |
| Equity ratio | End of the current fiscal period 34.9 / End of previous period 35 |
| Total assets | ¥51,760 million |
| Net assets | ¥18,385 million |
| Cash flows from operating activities | ¥2,978 million |
| Cash flows from investing activities | ¥-4,574 million |
| Cash flows from financing activities | ¥-1,127 million |
| Cash and cash equivalents at end of period | ¥7,078 million |
| Full-year earnings forecast | Net Sales ¥37,000 million (YoY +11.3%) / Operating profit ¥2,000 million (YoY +28.0%) / Ordinary income ¥1,600 million (YoY +20.0%) / Profit attributable to owners of the parent ¥1,100 million (YoY +0.7%) |
| Annual Dividend Forecast | ¥15 → ¥15（0.0%） |
| Payout ratio | Current fiscal year 41.6 % / Next-year forecast 41.3 % |
| Segment revenue | Contact Lenses and Lens Care Products ¥33,104,817 thousand (YoY +2.6%), Other ¥126,816 thousand (YoY +9.4%) |
| Segment profit | Contact Lenses and Lens Care Products ¥3,198,932 thousand (YoY -2.3%), Other ¥-8,961 thousand |
| Regional sales | ¥28,920,475 thousand, ¥1,108,754 thousand, ¥440,371 thousand, ¥2,739,229 thousand, ¥22,802 thousand |
| Depreciation and amortization | ¥3,319,505 thousand |
| Impairment loss | ¥8,788 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥4,066 thousand / Extraordinary loss Impairment Losses ¥8,788 thousand, Loss on Disposal of Fixed Assets ¥1,893 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | 連結子会社CLPL社が2025年4月1日付でScotlens Holdings Limitedの全株式を取得した。取得価額は￡2,404,187.50。 |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 30,265,922 |
| Treasury Shares at Period-End | 136 |
| Factors Behind Changes in Business Performance | 設備増設に比例した生産の実現に時間を要したことと、機械トラブルによりPureシリーズを中心に生産量が伸び悩み、予定通りの製品供給に至らなかった。利益面では、生産効率の低下による製造原価の高騰、円安による輸入価格の上昇、本社移転費用、人件費の増加、治験に伴う研究開発費の高水準が影響した。 |
Items this document does not state (3)
Revision to Earnings ForecastShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.設備増設に伴う生産の立ち上がりに時間を要したことや機械トラブルによる生産量の伸び悩みで製品供給が計画に届かなかった。さらに、生産効率の低下による製造原価の高騰、円安による輸入価格の上昇、本社移転費用、人員増加・処遇改善による人件費増加、治験に伴う研究開発費の高水準が利益を押し下げた。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.